How to Handle and Reserve Samples from BA / BE Studies
Recommendation
28/29 April 2026
From QbD to Process Validation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In April 2024, the draft document "Data Integrity for In Vivo Bioavailability and Bioequivalence Studies" was published on the US FDA website. The document is intended to assist applicants and marketing authorization holders (MAHs) in the area of data integrity for the clinical and bioanalytical part of bioequivalence and bioavailability studies.
In addition, a second guidance for study sponsors and/or drug manufacturers, contract research organizations (CROs), site management organizations (SMOs), clinical investigators, and independent third parties has been published. It is intended to provide recommendations regarding the procedure for handling reserve samples from relevant bioavailability (BA) and bioequivalence (BE) studies. The guidance highlights
- how the test article and reference standard for BA and BE studies should be distributed to the testing facilities,
- how testing facilities should randomly select samples for testing and material to maintain as reserve samples, and
- how the reserve samples should be retained.
More information is available in FDA's draft guideline Handling and Retention of Bioavailability and Bioequivalence Testing Samples.
Related GMP News
16.04.2026EMA Guidance on Conducting Clinical Trials during Public Health Emergencies
16.04.2026EMA accelerates Development of Medicines
16.04.2026What are the GMP Requirements for Drug Development?
26.03.2026FDA Guidance on Statistical Methods for Clinical Trials
26.03.2026Final ICH M11 CeSHarP Guideline
24.02.2026Good AI Practice in Drug Development